2. Parkinson’s Disease
Parkinson’s Disease is a
progressive condition involving
dysfunction or loss of dopamine
producing neurons in the brain.
Dopamine is a neurotransmitter
that aids the body’s ability to
carry out coordinated movement.
The hallmarks of the disease
are degeneration of
dopaminergic neurons in the
substantia nigra pars compacta
of the midbrain and the
presence of Lewy bodies.
The decreased levels of
dopamine that underlie the
disease are characterized by
difficulty with both voluntary
and involuntary movements.
It also involves non-motor
symptoms such as depression,
and orthostatic hypotension.
Parkinson’s disease classification
includes Juvenile Parkinson’s
Disease, Young-onset Parkinson’s
disease, and Idiopathic
Parkinson’s Disease. The female-
to-male ratio for prevalent cases
is different.
2
DelveInsight © 2019 | All rights reserved
3. Parkinson’s Disease total
prevalent population in
the 7MM* countries was
observed to be
1,608,367 in 2017 that is
expected to reach up to
1,706,922 by 2028,
growing at a CAGR of
0.54% for the study
period [2017–2028]. Parkinson’s disease
diagnosed prevalent
population was assessed
to be highest for the
United States, accounting
for 44.29% of the total
patient pool among the
7MM countries, which is
equivalent to 608,357
cases in 2017.
Parkinson’s Disease total
diagnosed prevalent
population ranged from
1,373,639 in 2017 to
1,536,230 in 2028,
growing at a CAGR of
1.02% for the study
period [2017–2028].
Among the EU-5 countries,
Germany witnessed the
highest diagnosed prevalent
population accounting for
more than 25.45% of the
total diagnosed cases,
followed by Italy and France
whereas Spain witnessed
the lowest number of
diagnosed cases in 2017.
Based on gender of the
prevalent population, it
was observed that more
than half of Parkinson’s
disease diagnosed
prevalent cases were
occupied by males, with
729,965 in the 7MM
countries in 2017, while
females accounted for
nearly 46.86% cases.
Parkinson’s Disease
Epidemiology
3
DelveInsight © 2019 | All rights reserved
*7MM includes:- United
States; EU-5 (Germany,
France, Spain, Italy,
United Kingdom); Japan.
4. Among the 7MM, the United
States accounted for the
majority of the market size
with USD 941.13 million
in 2017.
Parkinson’s disease market
size in the 7MM is expected to
reach USD 4356.14 million
by 2028 from USD 1837.90
million in 2017.
Gene therapy, by MeiraGTx
Holdings, AAV-GAD is
expected to grab the highest
market size with USD 1,609.40
million by 2028
Germany has the second
highest market size after the
United States in 2017, which is
accounted for USD 150.33
million.
Parkinson’s Disease Market
United States Market Size
Gene therapy
Market Size in 7MM
Germany Market Size
4
DelveInsight © 2019 | All rights reserved
5. 5
Drug - Istradefylline
Company - Kyowa Kirin
Parkinson’s Disease
Emerging Drugs and Companies
DelveInsight © 2019 | All rights reserved
Drug - Opicapone
Company- Neurocrine Biosciences
Drug - LY03003
Company- Luye Pharma
Drug - P2B001
Company - Pharma Two B Ltd
6. Complete Information
For complete information on
Parkinson’s Disease Market Insight, Epidemiology
and Market Forecast - 2028
please click the link below
Click here
OR
Write Us At
info@delveinsight.com
DelveInsight © 2019 | All rights reserved
6
7. 7
About DelveInsight
DelveInsight is a premier Business
Consulting and Market Research
firm focused exclusively on the
life science segment. With a wide
array of smart end-to-end
solutions, the firm helps the
global Pharmaceutical and Bio-
Tech companies formulate
prudent business decisions for
improving their performances to
stay ahead of the competitors.
ABOUT
MISSION
To provide “insights across the
value chain” and helping the
organization to take a prudent
business decision through the use
and analysis of actionable market
intelligence. The mission also is to
provide the most effective result
and efficient service with utmost
client care for maintaining a long-
term relationship with them.
To be the most trusted market
research & business consulting
firm in the world; and to
continue enable the Pharma &
Bio-Tech companies to achieve
their goals with the best
strategic insight and
competitive solution. The
vision also is inclusive of
becoming a one-stop solution
provider for the entire gamut
of drug development process.
VISION
MISSION
DelveInsight © 2019 | All rights reserved
8. DELVEINSIGHT
8
DelveInsight © 2019 | All rights reserved
Services Offerings by DelveInsight
FORECASTING
PIPELINE
CONSULTING
MARKET
INTELLIGENCE
OPPORTUNITY
ASSESSMENT
REPORT STORE
COMPETITIVE
ANALYSIS
PHARMDELVE
9. 9
DelveInsight © 2019 | All rights reserved
Contact Us
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight
